Drug Trial Radar · NCT07737665
Efficacy of Melatonin Treatment on Sleep Quality Improvement in Inflammatory Bowel Disease Patients With Clinical Remission
Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Apr 1, 2025
Primary completion
Apr 1, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Mahidol UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Sleep disturbances are common in patients with inflammatory bowel disease (IBD) and are associated with increased disease activity and reduced quality of life. Melatonin, a hormone regulating circadian rhythms, has shown potential anti-inflammatory and sleep-promoting effects in preliminary studies. This study aimed to evaluate the efficacy of melatonin supplementation on sleep quality in IBD patients in clinical remission.
Conditions
- IBD (Inflammatory Bowel Disease)
Interventions
Melatonin ("Circadin")Drug
2 mg of prolonged release melatonin was prescribed at a dose of one tablet daily, taken one hour before the participant's usual bedtime.
PlaceboDrug
placebo were manufactured to be identical in appearance
Primary outcomes
What the sponsor says the trial is designed to measure.
- PSQI (Pittsburgh Sleep Quality Index) score at 12th week of studyTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University 2 Wang Lang Rd
Bangkok Noi, Bangkok, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.